| abstract |
The present invention relates to imidazole derivatives of the general formula (I) in which R1 is halogen, lower alkoxyl or lower alkoxyl; R2 MEANS LOWER ALKYL, LOWER HYDROXYALKYL OR LOWER ALCOXYALKYL; R3 MEANS HYDROGEN, LOWER ALKYL, HYDROXYALKYL OR LOWER ALKOXYALKYL; Q MEANS EITHER N = EITHER CH =; R4 IS A GROUP OF FORMULA IIA OR IIB (FORMULA IIA AND IIB) IN WHICH X, Y AND Z REPRESENT INDEPENDENTLY? CH = OR? N = AND WHERE ONLY ONE OF X OR Y MAY BE A NITROGEN ATOM; R5 AND R6 REPRESENT INDEPENDENTLY HYDROGEN, LOWER ALKYL, LOWER HYDROXYALKYL, LOWER ALKOXYALKYL, (CH2) M- (CO) O-LOWER ALKYL, (CH2) MS (O) 2-LOWER ALKYL, (CH2) MC (O) -NR 'R' AND WHERE M = 0-3 AND R 'AND R' REPRESENT INDEPENDENTLY HYDROGEN OR LOWER ALKYL; AS WELL AS ON PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF. IT HAS BEEN NOW FOUND SURPRISINGLY THAT THE COMPOUNDS OF GENERAL FORMULA I ARE ANTAGONISTS OF THE METABOTROPIC GLUTAMATE RECEPTORS. THEY CAN BE USED IN THE TREATMENT OR PREVENTION OF MEDIATION DISORDERS BY THE MGLUR5 RECEPTOR. |